What is 10X Science?
10X Science operates at the intersection of biotechnology and artificial intelligence, providing a sophisticated platform designed to streamline protein characterization. The company addresses a fundamental bottleneck in modern drug discovery: the manual, time-intensive analysis of experimental protein data. By automating these workflows through machine learning-driven interpretation, 10X Science enables research organizations to evaluate drug candidates with greater consistency and reduced error rates. This technological approach not only optimizes internal R&D workflows but also strengthens the overall decision-making framework for pharmaceutical developers, ultimately shortening the time-to-market for novel therapeutics. As the industry shifts toward data-centric discovery models, 10X Science is emerging as a critical infrastructure provider for the next generation of biopharma innovation.
How much funding has 10X Science raised?
10X Science has raised a total of $4.8M across 1 funding round:
Seed
$4.8M
Seed (2026): $4.8M with participation from Civilization Ventures, Initialized Capital, and Y Combinator
Key Investors in 10X Science
Civilization Ventures
Civilization Ventures is a venture capital firm that invests in innovative companies within the health tech and biopharma sectors, focusing on preventative, personalized, and regenerative healthcare solutions.
Initialized Capital
Initialized Capital is a venture capital firm dedicated to supporting seed stage founders across various sectors including enterprise SaaS, sustainability, health, hard tech, and artificial intelligence.
Y Combinator
Established in 2005, Y Combinator provides seed funding for startup businesses and acts as a premier accelerator for high-growth technology companies.
What's next for 10X Science?
Looking ahead, the strategic deployment of this capital will likely focus on expanding the company's computational infrastructure and deepening its market penetration within the global biopharma ecosystem. With the support of high-profile backers, 10X Science is poised to refine its predictive models and potentially integrate additional multi-omics data streams into its existing platform. The focus remains on scaling the enterprise-grade features of its software to meet the rigorous demands of large-scale clinical research environments. By maintaining its commitment to reducing reliance on manual analysis, the company is well-positioned to capture significant market share, driving long-term value for stakeholders while fundamentally altering the economics of therapeutic development. Future growth will likely be defined by strategic partnerships and the continued evolution of its AI-driven diagnostic and discovery tools.
See full 10X Science company page
